by Sermonix Pharmaceuticals | Apr 29, 2024 | News
‘Significant and clinically meaningful’ results support Sermonix’s plans to study oral lasofoxifene’s impact on VVA in women with mBC being treated in ELAINE-3 trial COLUMBUS, Ohio, April 29, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a...
by Sermonix Pharmaceuticals | Apr 22, 2024 | News
COLUMBUS, Ohio, Apr. 22, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today announced it will host a...
Recent Comments